TCIM
TOVX icon

TIAA CREF Investment Management’s Theriva Biologics TOVX Stock Holding History

TIAA CREF Investment Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-29
Closed -$162K – 3175
2017
Q1 		$162K Sell
29
-1
-3% -$6.98K ﹤0.01% 3018
2016
Q4 		$200K Buy
30
+1
+3% +$10.3K ﹤0.01% 3043
2016
Q3 		$430 Sell
29
-2
-6% -$29.9K ﹤0.01% 2912
2016
Q2 		$486K Buy
+31
New +$584K ﹤0.01% 2871

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

TIAA CREF Investment Management's TOVX Position: Q2 2017 in Review

TIAA CREF Investment Management sold out of Theriva Biologics (TOVX) in Q2 2017, closing a stake of 29 shares — an estimated $162K sold.

TIAA CREF Investment Management first reported a position in TOVX in Q2 2016 and held it in 4 quarters. The position peaked at $486K in Q2 2016. 53 funds tracked by Wall St. Rank hold TOVX as of Q2 2017.

  • TIAA CREF Investment Management reported no remaining Theriva Biologics position as of Q2 2017 after selling out during the quarter.
  • TIAA CREF Investment Management sold 29 Theriva Biologics shares in Q2 2017, an estimated $162K.
  • TIAA CREF Investment Management first reported a position in Theriva Biologics in Q2 2016 and held it in 4 quarters.
  • TIAA CREF Investment Management's Theriva Biologics position peaked at $486K in Q2 2016.
  • 53 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2017.

Based on TIAA CREF Investment Management's 13F filing for Q2 2017, filed 10 Aug 2017.